Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Crizotinib vs Standard Chemotherapy in ALK-positive Advanced NSCLC
2009-012595-27Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of crizotinib in ALK-positive non-small cell lung cancer (2 arms), sponsored by Pfizer. Started Oct 2009; status: completed.
02
Drugs
crizotinib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on 2009-012595-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012595-27.